Candidate genes implicated in type 1 diabetes suceptibility

Current Diabetes Reviews

Volumn 4, Issue 2, 2008, Pages 110-121

  Aribi, Mourad ^a  

^a UNIVERSITY OF TLEMCEN   (Algeria)

Author keywords

Candidate genes; Identification strategies; Type 1 diabetes susceptibility

Indexed keywords

AUTOANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; GLUTAMATE DECARBOXYLASE ANTIBODY; HEAT SHOCK PROTEIN; HLA A ANTIGEN; HLA ANTIGEN; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; INSULIN ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; LYMPHOTOXIN; MACROPHAGE MIGRATION INHIBITION FACTOR; PANCREAS ISLET CELL ANTIBODY; SUMO 4 PROTEIN; SUMO PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNITY; B LYMPHOCYTE; CELL DESTRUCTION; CHROMOSOME 11P; CHROMOSOME 12Q; CHROMOSOME 22Q; CHROMOSOME 6P; CHROMOSOME 6Q; CYTOKINE PRODUCTION; DENDRITIC CELL; ENVIRONMENTAL FACTOR; ETHNICITY; FAMILY HISTORY; FAMILY STUDY; GENE IDENTIFICATION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; IMMUNE RESPONSE; IMMUNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; LINKAGE ANALYSIS; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MOLECULAR BIOLOGY; MOLECULAR EPIDEMIOLOGY; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TWINS; VARIABLE NUMBER OF TANDEM REPEAT;

AGE OF ONSET; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 6; DIABETES MELLITUS, TYPE 1; FAMILY; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HLA ANTIGENS; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; LINKAGE DISEQUILIBRIUM; LOD SCORE; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MINISATELLITE REPEATS; RISK FACTORS; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS;

EID: 48749132434     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339908784220723     Document Type: Review

References (151)

1. American Diabetes Association. Report ofthe expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-97.
2. Bourcigaux N, Charbonnel B. Diabète insulino-dépendaht: Etiologie, physiopathologie, diagnostic, complications, pronostic, traitement. Rev Prat. 1997; 47: 1583-92.
3. Pitkäniemi J, Onkamo P, Tuomilehto J, Arjas E. Increasing incidence of Type 1 diabetes - role for genes? BMC Genet 2004; 5: 5.
4. Onkamo P, Väänänen S, Karvonen M, Tuomilehto J. Worldwide increase in incidence of type I diabetes: the analysis of the data on published incidence trends. Diabetologia 1999; 42: 1395-403.
5. Molbak AG, Christau B, Mamer B, Borch-Johnsen K, Nerup J. Incidence of insulin-dependent diabetes mellitus in age groups over 30 years in Denmark. Diabet Med 1994; 11: 650-5.
6. Rothe H, Haussmmann A, Casteels K, el al. IL-18 inhibits diabetes development in non-obese diabetic mice by counterregulation of Th1-dependent destructive insulitis. J immunol 1999; 163: 1230-6.
7. Özer G, Teker Z, Cetiner S, et al. Serum IL-1, IL-2, TNF-α and IFN-γ levels of patients with type 1 diabetes mellitus and their siblings. J Pediatr Fndocrinol Metab 2003; 16: 203-10.
8. Erbaǧci AB, Tarakcioglu M, Coskun Y, Sivasli E, Sibel Namiduru E. Mediators of inflammation in children with type 1 diabetes mellitus: cytokines in type 1 diabetic children. Clin Biochem 2001: 34: 645-50.
9. Kulmala P, Savola K, Petersen JS, et al. Prediction of insulin-dependent diabetes mellitus in siblings of children with diabetes. A population-based study. The Childhood Diabetes in Finland Study Group. J Clin Invest 1998; 101: 327-36.
10. Gorus FK, Vandewalle CL, Winnock F, et al. Increased prevalence of abnormal immunoglobulin M, G, and A concentrations at clinical onset of insulin-dependent diabetes mellitus: a registry-based study. The Belgian Diabetes Registry. Pancreas 1998; 16: 50-9.
11. Honeyman M, Wasserfall C, Nerup J, Rossini A. Prediction and prevention of IDDM. Diabetologia 1997; 40: B58-61.
12. Thomson G. HLA disease associations: models for insulin dependent diabetes mellitus and the study of complex human genetic disorders. Annu Rev Genet 1988; 22: 31-50.
13. Todd JA, Aitman TJ, Comall RJ, et al. Genetic analysis of a complex, multifactorial disease, autoimmune type 1 (insulin-dependent) diabetes. Res Immunol 1991; 142: 483.
14. Todd JA, Bain SC. A practical approach to identification of susceptibility genes for IDDM. Diabetes 1992; 41: 1029-34.
15. Deschamps I, Boitard C, Hors J, et al. Life table analysis of the risk of type 1 (insulin-dependent) diabetes mellitus in siblings according to islet cell antibodies and HLA markers: an 8-year prospective study. Diabetologia 1992; 35: 951-7.
16. Devendra D, Liu E, Eisenbarth GS. Type 1 diabetes: recent developments. BMJ 2004; 328: 750-4.
17. Leslie RDG, Delli Castelli M. Age-Dependent Influences on the Origins of Autoimmune Diabetes. Evidence and Implications. Diabetes 2004; 53: 3033-40.
18. Hyttinen V, Kaprio J, Kinnonen L, Koskenvuo M, Tuomilehto J. Genetic liability of type 1 diabetes and the onset aee amona 22,650 young finnish twin pairs: a nationwide follow-up study. Diabetes 2003; 52: 1052-5.
19. Redondo MJ, Yu L, Hawa M, et al. Heterogeneity of type I diabetes: analysis of monozygotic twins in Great Britain and the United States. Diabetologia 2001; 44: 354-62.
20. Kumar D, Gemayel NS, Deapen D, et al. North-American twins with IDDM: genetic, etiological, and clinical significance of disease concordance according to age, zygosity, and the interval after diagnosis in first twin. Diabetes 1993; 42: 1351-63.
21. Salvetti M, Ristori G, Bomprezzi R, Pozzilli P, Leslie RDG. Twins: mirrors of the immune system. Immunol Today 2000; 21: 342-7.
22. Writing Group for the SEARCH for Diabetes in Youth Study Group, Dabelea D, Bell RA, et al. Incidence of diabetes in youth in the United States. JAMA 2007; 297: 2716-24. [published erratum appears In JAMA 2007; 298: 627].
23. SEARCH for Diabetes in Youth Study Group, Liese AD, D'Agostino RB Jr, et al. The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics 2006; 118: 1510-8.
24. Moore KR, Harwell TS, McDowall JM, Helgerson SD, Gohdes D. Three-year prevalence and incidence of diabetes among American Indian youth in Montana and Wyoming, 1999 to 2001. J Pediatr 2003; 143: 368-71.
25. Robert JJ, Darmaun D, Reach G, Lestradet H. Blood and urinary glucose for optimal control of diabetes in children. Ann Pediatr (Paris) 1986; 33: 904-6.
26. Tubiana RN. Diagnostic des diabètes de l'enfant. Rev Prat 1996; 46: 552-5.
27. Fajans SS, Bell GL, Boweden DW, Halter JB, Polonsky KS. Maturity Onset Diabetes of the young. Life sci 1994; 55: 413-22.
28. Lestradet H, Deschamps J, Tichet J, Lestradet OM. Hyperglycémie chronique non insulino prive de l'enfant. Arch Fr Pediatr 1989; 46: 19-23.
29. Field LL. Genetic linkage and association studies of type 1 diabetes: challenges and rewards. Diabetologia 2002; 45: 21-35.
30. Bennett ST, Todd JA. Human type 1A diabetes and the insulin gene: principles of mapping polygenes. Annu Rev Genet 1996; 30; 343-70.
31. Juliet C, Hyer RN, Davies J, et al. Insulin-IGF2 region on chromosome 11p encodes a gene implicated in HLA-DR4-dependent diabetes susceptibility. Nature 1991; 354: 155-9.
32. Bonifacio E, Hummel M, Walter M, Schmid S, Ziegler AG. IDDM1 and multiple family history of type 1 diabetes combine to identify neonates at high risk for type 1 diabetes. Diabetes Care 2004; 27: 2695-700.
33. Bach JF. L'origine immunitaire du diabète. Recherche 1989; 214: 1206-15.
34. Kim CS, Song MK, Park JS, et al. The clinical and immumogenetic characteristics of adult-onset type 1 diabetes mellitus in Korea. Acta Diabetol 2007; 44: 45-54.
35. Horton V, Stratton I, Bottazzo GF, et al. Genetic heterogencity of autoimmune diabetes: age at presentation in adults is influenced by HLA DRB1 and DQB1 genotypes (UKPDS 43). Diabetologia 1999; 42: 608-16.
36. Pozzilli P, Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention. Diabetes Care 2001; 24: 1460-7.
37. Turner R, Stratton I, Horton V, et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes: UK Prospective Diabetes Study Group. Lancet 1997; 350: 1288-93.
38. Clayton DG, Walker NM, Smyth DJ, et al. Population structure, differential bias and genomic control in a large-scale, case-control association study. Nat Genet 2005; 37: 1243-6.
39. Kauppi L, Sajantila A, Jeffreys AJ. Recombination botspots rather than population history dominate linkage disequilibrium in the MHC class II region. Hum Mol Genet 2003; 12: 33-40.
40. France. In: Cavalli-Sforzi LL, Menozzi P, Piazza A Ed, The history and geography of human genes. Princeton, Princeton University Press. 1993; 280-5.
41. Anne Cambon Thomsen, editor. 440. De la génétique des populations à la génétique épidémiologique et à la santé publique. Génétique, Populations et Maladies; 2002 July 19; Université de tous les savoirs, France.
42. Vaessen N, Heutink P, Houwing-Duistermaat JJ, et al. A genomewide search for linkage-disequilibrium with type 1 diabetes in a recent genetically isolated population from the Netherlands. Diabetes 2002; 51: 856-9.
43. Kyvik KO, Green A, Beck-Nielsen H. Concordance rates of insulin dependent diabetes mellitus: a population based study of young Danish twins. BMJ 1995; 311: 913-7.
44. Kaprio J, Tuomilehto J, Koskenvuo M, et al. Concordance for type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus in a population-based cohort of twins in Finland. Diabetologia 1992; 35: 1060-7.
45. Gillespie KM, Gale EAM, Bingley PJ. High Familial Risk and Genetic Susceptibility in Early Onset Childhood Diabetes. Diabetes 2002; 51: 21-4.
46. Hathout EH, Hartwick N, Fagoaga OR, et al. Clinical, autoimmune, and HLA characteristics of children diagnosed with type 1 diabetes before 5 years of age. Pediatrics 2003; 111: 860-3.
47. Redondo MJ, Rewers M, Yu L, et al. Genetic determination of islet cell autoimmunity, in monozygotic twin, dizygotic twin, and non-twin siblings of patients with type 1 diabetes: prospective twin study. BMJ 1999; 318: 698-702.
48. Rich SS, Concannon P. Challenges and strategies for investigating the genetic complexity of common human diseases. Diabetes 2002; 51 (Suppl 3): S288-94.
49. Caillat-Zucman S. Prix Apollinaire Bouchardat 2000. Approche immunogénétique du diabète de type 1 chez l'homme. J Annu Diabetol Hotel Dieu 2000; 39-51.
50. Morton NE. Sequential tests for the detection of linkage. Am J Hum Genet 1955; 7: 277-318.
51. Desmarais E, Vigneron S, Buresi C, Roizès G. Détection du polymorphisme dans l'ADN. Application en biologie et médecine diagnostique, épidémiologique, et pronostique. Paris: Les Editions INSERM 1995.
52. Johnston C, Pyke DA, Cudworth AG, Wolf E. HLA-DR typing in identical twins with insulin-dependent diabetes: difference between concordant and discordant pairs. Br Med J 1983; 286: 253-5.
53. Viv Bewick, Liz Cheek, Jonathan Ball. Statistics review 11: Assessing risk. Crit Care 2004; 8: 287-91.
54. Vance Berger W, Jialu Zhang. Case-Control Studies. Encyclopedia of Statistics in Behavioral Science. Article Online Posting Date: October 15, 2005. DOI: 10.1002/0470013192,bsa073.
55. Deeks J. When can odds ratios mislead? Odds ratios should be used only in case-control studies and logistic regression analyses. Br Med J 1998 317: 1155-6.
56. Sue Kirkman M. A crash course in stats. DOC News 2007; 4: 2.
57. Bland JM, Altman DG. Statistics notes. The odds ratio. BMJ 2000; 320: 1468.
58. Sim J, Reid N. Statistical inference by confidence intervals: issues of interpretation and utilization, Phys Ther 1999; 79: 186-95.
59. Danze PM, Penet S, Fajardy I. La génétique du diabète insulinodépendant. Intérêt dans la pratique biologique. Ann Biol 1997; 55: 537-44.
60. Faas S, Trucco M. The genes influencing the susceptibility to IDDM in humans. J Endocrinol Invest 1994; 17: 477-95.
61. Garchon HJ, Bach JF. The contribution of non-MIIC genes to susceptibility to autoimmune diseases. Hum Immunol 1991; 32: 1-30.
62. Florez JC, Hirschhorn J, Altshuler D. The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits. Annu Rev Genomics Hum Genet 2003; 4: 257-91.
63. Meyer D, Thomson G. How selection shapes variation of the human major histocompatibility complex: a review. Ann Intern Med 2001; 65: 1-26.
64. Akerblom HK, Knip M, Simell O. From pathomecanisms to prediction, prevention and improved care of insulin-dependent diabetes mellitus in children. Ann Med 1997; 29: 383-5.
65. Scott FW, Norris JM, Kolb H. Milk and type 1 diabetes. Diabetes Care 1996; 19: 379-83,
66. Atkinson MA, Eisenbarth GS. Type 1A diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001; 358: 221-9.
67. Abiru N, Kawasaki E, Eguch K. Current knowledge of Japanese type 1 diabetic syndrome. Diabetes Metab Res Rev 2002; 18: 357-66.
68. Todd JA. Lawrence Lecture; The emperor's new genes: 1993 RD Lawrence lecture. Diabet Med 1994: 11: 6-16.
69. Thorsby E, Ronningen K. Particular HLA-DQ molecules play a dominant role in determining susceptibility or resistance to type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1993; 36: 371-7.
70. Risch N. Assessing the role of HLA-linked and unlinked determinants of disease. Am J Hum Genet 1987; 40: 1-14.
71. Rotter J, Landaw E. Measuring the genetic contribution of a single locus to a multilocus disease. Clin Genet 1984; 26: 529-42.
72. Amirzargar A, Mostafavi H, Farjadian SH, Ghaderi A. Association of HLA-class II alleles and susceptibility to type 1 diabetes in southern Iranian patients. Int J Med Sci 2000; 25: 109-13.
73. Sanjeevi CB. HLA-DQ6-mediated protection in IDDM. Hum Immunol 2000; 61: 148-53.
74. Lie BA, Todd JA, Pociot F, et al. The predisposition to type I diabetes linked to the human leukocyte antigen complex includes at least one non-class II gene. Am J Hum Genet 1999; 64: 793-800.
75. Nejentsev S, Reijonen H, Adojaan B, et al. The effect of HLA-B allele on the IDDM risk defined by DRB1*04 subtypes and DQB1*0302, Diabetes 1997; 46: 1888-92.
76. Jiwa F. Diabetes in the 1990s-an overview. Statistical Bulletin 1997, Jan-Mar, 2-8.
77. Kockum I, Sarjeevi CB, Eastman S, Landin-Olsson M, Dahlquist G, Lemmark A. Population analysis of protection by HLA-DR and DQ genes from insulin-dependent diabetes mellitus in Swedish children with insulin-dependent diabetes and controls. Eur J Immunogenet 1995; 22: 443-65.
78. Aribi M, Moulessehoul S, Benabadji AB, Kendoucitani M. HLA DR phenotypic frequencies and genetic risk or Type I diabetes in west region ofAlgeria, Tlemcen. BMC Genet 2004; 5: 24.
79. Djoulah S, Khalil I, Beressi JP, et al. The HLA-DRBI*0405 haplotype is most strongly associated with IDDM in Algerians. Eur J Immunogenet 1992; 19: 381-9.
80. Jasinski JM, Eisenbarth GS. Hypothesis for the pathogenesis of type IA diabetes. Drugs Today (Barc) 2005; 41: 141-9.
81. Ziegler M, Ziegler B. Immunological disorders of type I diabetes mellitus. Exp Clin Endocrmol 1989; 94: 97-114.
82. Aucoutirier P, Caillat-Zucman S, Garchon HJ, Bach JF. In: Bach JF, Chatenoud L Ed, Molecules de reconnaissance. Paris, Flammarion Médecine Sciences. 2002; 7-59.
83. Poncet P, Arock M, David B. MHC class II-dependent activation of CD4+ T cell hybridomas by human mast cells through superantigen presentation. J Leukoc Biol 1999; 66: 105-12.
84. Frandji P, Oskeritzian C, Cacaraci F, et al. Antigen-dependent stimulation by bone marrow-derived mast cells of MHC class II-restricted T cell hybridoma. J Immunol 1993; 151: 6318-28.
85. Pugliese A, Bugawan T, Moromisato R, et al. Two subsets of HLA-DQ-A1 alleles mark phenotypic variation in levels of insulin autoantibodies in first degree relatives at risk for insulin-dependent mellitus. J Clin Invest 1994; 93: 2447-52.
86. Demaine AG, Hibberd ML, Mangles D, Millward BA. A new marker in the HLA class I region is associated with the age at onset of IDDM. Diabetologia 1995; 38: 623-8.
87. Timist J. Etiopathogénie du diabèe de type I. Rev Prat 1996; 46: 560-4.
88. Svejgaard AP, Platz P, Ryder LP. HLA and disease: a survey. Immunol Rev 1982; 70: 193-218.
89. Khalil I, Deschamps I, Lepage V, Aladaccak R, Degos L, Hors J. Dose effect.of cis and trans encoded HLA-DQalphabeta heterodimers in IDDM susceptibility. Diabetes 1992; 41: 378-84.
90. Feingold J. Le dégéquilibre de liaison. Med Sci (Paris) 1991; 7: 161-8.
91. Agardh D, Gaur LK, Agardh E, Landin-Olsson M, Agardh CD, Lernmark A. HLA-DQBI*0201/0392 is associated with severe retinopathy in patients with IDDM. Diabetologia 1996; 39: 1313-7.
92. Mimura T, Funatsu H, Uchigata Y, et al. Glutamic acid decarboxylase autoantibody prevalence and association with HLA genotype in patients with younger-onset type 1 diabetes and proliferative diabetic retinopathy. Ophthalmology 2005; 112: 1904-9.
93. Mimura T, Funatsu H, Uchigata YK, et al. Relationship between human leukocyte antigen status and proliferative diabetic retinopathy in patients with younger-onset type 1 diabetes mellitus. Am J Ophthalmol 2003; 135: 844-8.
94. Tait BD, Drummond BP, Varney MD, Harrison LC. HLA-DRB1 *0401 is associated with susceptibility to insulin-dependent diabetes mellitus independently of the DQB1 locus. Eur J Immunogenet 1995; 22: 289-97.
95. Dorman J, the WHO DiaMon Molecular Epidemiologie Sub-Project Group. Molecular Epidemiology of Insulin-dependent Diabetes Mellitus: WHO Diamon Project. Gac Med Mex 1997; 133 (Suppl 1): 151-4.
96. Setien Baranda F, Coto E, Menendez Diaz J, Martinez-Naves E, Alvarez Martinez V, Lopez-Larrea C. HLA class II and susceptibility and resistance to insulin-dependent diabetes mellitus in a population from the northwest of Spain. Eur J Immunogenet 1994; 21: 219-29.
97. Todd JA, Bell JI, McDevitt HO. HLA antigens and insulin-dependent diabetes. Nature 1988; 333: 710.
98. Kalil I, d'Auriol L, Gobet M, et al. A combination of HLA-DQ beta Asp57-negative and HLA DQalpha Arg52 confers susceptibility to insulin-dependent diabetes mellitus. J Clin Invest 1990; 85: 1315-9.
99. Kla KKino Y, Ito T, Hirai H, Nakamura Knimunogenetics of insulin-dependent diabetes mellitus. Acta Paediatr 1999; Suppl 427: 3-7.
100. Davies JL, Kwaguchi Y, Bennett ST, et al. A genome-wide search for human type I diabetes susceptibility genes. Nature 1994; 371: 130-6.
101. Noso S, Ikegami H, Fujisawa T, et al. Genetic heterogeneity in association of the SUM04 M55 Variant with susceptibility to type 1 diabetes. Diabetes 2005; 54: 3582-6.
102. Ksoy R, Concannon P. Functional variants in SUMO4, TAB2, and NFkappaB and the risk of type I diabetes. Genes Immun 2005, 6: 231-5.
103. Bohren M, Nadkarni VSong JH, Gabbay K, Owerbach D. A M55 polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus. J Biol Chem 2004; 279: 27233-8.
104. Guo D, Li M, Kang Y, et al. Functional variant of SUMO4, a new I kappa B alpha modifici, is associated with type I diabetes. Nat Genet 2004; 36: 837-41. published erratum appears In Nat Genet 2004; 36: 1024].
105. Adler T, Akiyama H, Herder C, Klb H, Burkart VHeat shock protein 60 elicits abnormal response in macrophages of diabetes-prone non-obese diabetic mice. Biochem Biophys Res Common 2002; 294: 592-6.
106. Horvath L, Cervenak L, Oroszlan M, et al. Antibodies against different epitopes of heat-shock protein 60 in children with type I diabetes mellitus. Immunol Lett 2002; 80: 155-62.
107. Birk OS, Elias D, Weiss AS, et al. NOD Mouse diabetes: the ubiq uitous mouse hsp60 is a beta-cell target antigen of autoimmune T cells. J Autoimmun 1996; 9: 159-66.
108. Jones DB, Coulson AF, Duff GW. Sequence homologies between hsp60 and autoantigens. Immunol Today 1993; 14: 115-8.
109. Devendra D, Eisenbarth GS. Immunologic endocrine disorders. J Allergy Clin Immunol 2003; 111: 624-36.
110. Achenbach P, Bonifacio E, Egler AG. Predicting type I diabetes. Curr Diab Rep 2005; 5: 98-103.
111. Rani R, Sood A, Goswami R. Molecular basis of predisposition to develop type 1 diabetes mellitus in North Indians. Tissue Antigens 2004; 64: 145-55.
112. Guja C, Guja L, Nutland S, Rance H, Todd JA, Ionescu-Tirgoviste C. Strong association of insulin gene INS-MTR polymorphisms with type I diabetes in the Romanian population, Rom J Interm Med 2004; 42: 313-23.
113. Vandewalle CL, Falorni A, Lernmark Å et al. Associations of GAD-65 and IA-2-autoantibodies with genetic risk markers in new-onset IDDM patients and their siblings. Diabetes Care 1997; 10: 1547-52.
114. Perez de Nanclares G, Bilbao JR, Castano L. No association of INS-MTR genotype and IAA autoantibodies. Ann N Y Acad Sei 2004, 1037: 127-30.
115. ODell SD, Bujac SR, Miller GJ, Day IN. Associations of IGF2 Apal RFLP and INS MTR class I allele size with obesity. Eur. J Hum Genet 1999; 7: 821-7.
116. Walter M, Albert E, Conrad M, et al. IDDM2insulin MTR modifies risk conferred by IDDMIHLA for development of Type I diabetes and associated autoimmunity. Diabetologia 2003; 46: 712-20.
117. Ibanez. L, Ong KPotau N, Marcos MVde Zgher F, Dunger D. Insulin gene variable number of tandem repeat genotype and the low birth weight, precocious pubarche, and hyperinsulinism seqence. J Clin Endocrinol Metab 2001; 86: 5788-93.
118. Miadis P, Bennett ST, Todd JA, et al. Insulin expression in human thymus is modulated by INS MTR alleles at the IDDM2 locus. Nat genet 1997; 15: 289-92.
119. Miadis P, Ounissi-Benkalha H, Palumbo M, et al. Class III alleles of the variable number of tandem repeat insulin polymorphism associated with silencing of thymic insulin predispose to type I diabetes. J Clin Endocrinol Metab 2001; 86: 3705-10.
120. Rodriguez S, Gaunt TR, ODell SD, et al. Haplotypic analyses of the IGF2-INS-TH gene cluster in relation to cardiovascular risk traits. Hum Mol Genet 2004; 13: 715-25.
121. Metcalfe K, Hitman GA, Rowe RE, et al. Concordance for type 1 diabetes in identical twins is affected by insulin genotype. Diabetes Care 2001; 838-42.
122. Lee M, Chuang E, Griffin M, et al. Molecular basis of T cell inactivation by CTLA-4. Science 1998; 282: 2263-6.
123. Barker JM. Clinical review: Type 1 diabetes-associated autoimmunity: natural history, genetic associations, and screening. J Clin Endocrinol Metab 2006; 91: 1210-7.
124. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5: 443-53.
125. Vsu C, Wang A, Gorla SR, Kithamana S, Prabhakar BS, Holterman MJ. CD80 and CD86 C domains play an important role in receptor binding and co-stimulatory properties. Int Immunol 2003; 15: 167-75.
126. Mdya B, Pearce S. The emerging role of the CTLA-4 gene in autoimmune endocrinopathies. Eur J Endocrinol 2004; 150: 619-26.
127. Janeway CA, Travers P, Walport M, Shlomick M. Immunobiology 5: The immune system in health and disease. 5th ed. New York and London: Garland Publishing, 2001.
128. Kn MS, Polychronakos C. Immunogenetics of type 1 diabetes. Horm Res 2005; 64: 180-8.
129. Steck AK Bugawan TL, Mdes AM, et al. Association of non-HLA genes with type 1 diabetes autoimmunity. Diabetes 2005; 54: 2482-6.
130. Kvvoura FK Ioannidis JP. CTLA-4 gene polymorphisms and susceptibility to type 1 diabetes mellitus: a HuGE Review and meta-analysis. Am J Epidemiol 2005; 162: 3-16.
131. Mojtahedi ZOmrani GR, Doroudchi M, Ghaderi A. CTLA-4 49 AG polymorphism is associated with predisposition to type 1 diabetes in Iranians. Diabetes Res Clin Pract 2005; 68: 111-6.
132. Barreto M, Santos E, Ferreira R, et al. Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus. Eur J Hum Genet 2004; 12: 620-6.
133. Frydecka I, Daroszewski J, Suwalska K et al. CTLA-4 (CD 152) gene polymorphism at position 49 in exon 1 in Graves' disease in a Polish population of the Lower Silesian region. Arch Immunol Titer Exp (Warsz) 2004; 52: 369-74.
134. Chistiakov DA. Immunogenetics of Hashimotos thyroiditis. J Autoimmune Dis 2004; 2: 1.
135. Chistiakov DA, Turakulov RI. CTLA-4 and its role in autoimmune thyroid disease. J Mol Endocrinol 2003; 31: 21-36.
136. Kstiansen OP, Larsen M, Pociot F. CTLA-4 in autoimmune diseases-a general susceptibility gene to autoimmunity? Genes Immun 2000; 1: 170-84.
137. Anjos S, Polychronakos C. Mechanisms of genetic susceptibility to type 1 diabetes: beyond HLA. Mol Genet Metab 2004; 81: 187-95.
138. Chistiakov DA, Savostanov KNosikov. VCTLA4 gene polymorphisms are associated with, and linked to, insulin-dependent diabetes mellitus in a Russian population. BMC Genet 2001; 2: 6.
139. Purohit S, Podolsky R, Collins C, et al. Lack of correlation between the levels of soluble cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and the CT-60 genotypes. J Autoimmune Dis 2005; 2: 28.
140. Ueda H, Howson JM, Esposito L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423: 506-11.
141. Magistrelli G, Jcannin P, Herbault N, et al. A soluble form of CTLA-4 generated by alternative splicing is expressed by non-stimulated human T cells. Eur J Immunol 1999; 29: 3596-602.
142. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003; 3: 791-800.
143. Froidevaux C, Roger T, Martin C, Glauser MP, Calandra T. Macrophage migration inhibitory factor and innate immune responses to bacterial infections. Crit Care Med 2001; 29 (Suppl 1): S13-5.
144. Shimizu T. Role of macrophage migration inhibitory factor (MIF) in the skin. J Dermatol Sci 2005; 37: 65-73.
145. Shimizu T, Nishihira J, Watanabe H, et al. Macrophage migration inhibitory factor is induced by thrombin and factor Xa in endothelial cells. J Biol Chem 2004; 279: 13729-37.
146. Nguyen MT, Beck J, Lue H, et al. The A 16-residue peptide fragment of macrophage migration inhibitory factor, MIF-(50-65), exhibits redox activity and has MIF-like biological functions. J Biol Chem 2003; 278: 33654-71.
147. Murakami H, Akbar SM, Matsui H, Horiike N, Onji M. Macrophage migration inhibitory factor activates antigen-presenting dendritic cells and induces inflammatory cytokines in ulcerative colitis. Clin Exp Immunol 2002; 128: 504-10.
148. Potolicchio I, Santambrogio L, Strominger JL. Molecular interaction and enzymatic activity of macrophage migration inhibitory factor with immunorelevant peptides. J Biol Chem 2003; 278: 30889-95.
149. Sakai Y, Masamune A, Satoh A, Nishihira J, Yamagiwa T, Shimosegawa T. Macrophage migration inhibitory factor is a critical mediator of severe acute pancreatitis. Gastroenterology 2003; 124: 725-36.
150. Al-Abed Y, Cvetkovic I, Miljkovic D, Metz C, Nicoletti F, Stosic-Grujicic S, editors. MEDI 581. MIF knockout mice are resistant to the development of type 1 diabetes. 229th American Chemical Society National Meeting & Exposition; 2005 March 13-17; San Diego, CA, USA.
151. Cvetkovic I, Al-Abed Y, Miljkovic D, et al. Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes. Endocrinology 2005; 146: 2942-51.